# KB803 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kb803

> The next catalyst for KB803, sponsored by Krystal Biotech, Inc. (KRYS), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KB803 |
| Codes | KB803 |
| Sponsor | Krystal Biotech, Inc. (KRYS) https://sec-api.dev/companies/krys/catalysts |
| Indications | Dystrophic Epidermolysis Bullosa |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-08-04, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001711279-26-000071): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm
- SEC Form 10-Q (accession 0001711279-26-000057): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm
- SEC Form 10-Q (accession 0001711279-26-000043): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000043/krys-20260331.htm
- SEC Form 10-K (accession 0001711279-26-000016): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, decentralized, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm
- SEC Form 10-Q (accession 0001711279-25-000087): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 registrational study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm
- SEC Form 10-Q (accession 0001711279-25-000077): "In June 2025, we announced that we dosed the first patient in IOLITE, an intra-patient, double-blind, placebo-controlled, multicenter Phase 3 study with a crossover design to evaluate KB803 for the treatment and prevention of corneal abrasions in DEB patients, six months of age or older." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000077/krys-20250630.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-02-17, last confirmed 2026-08-03.
- Press release filed with the SEC (EX-99) (accession 0001711279-26-000058): "The Company's registrational, intra-patient, double-blind, de-centralized, placebo-controlled study (IOLITE) with crossover design evaluating KB803 for the treatment and prevention of corneal abrasions in DEB patients was fully enrolled in April and is on track for a top-line data readout in 4Q 2026." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm
- SEC Form 10-K (accession 0001711279-26-000016): "We continue to enroll patients in IOLITE and expect to complete enrollment in the first half of 2026 and report top-line results later in 2026." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm
- SEC Form 10-K (accession 0001711279-26-000016): "We expect to complete enrollment in IOLITE in the first half of 2026 and report top-line results later in 2026." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000016/krys-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-26-000018): "The Company expects to complete enrollment in 1H 2026 and report top-line results before year end." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000018/a4q25exhibit991pr.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07016750 (A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Krystal Biotech, Inc.." https://clinicaltrials.gov/study/NCT07016750

### Feb 2027: topline data readout

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2026-11-02, last confirmed 2026-11-16T22:20:01.192Z.
- SEC Form 10-Q (accession 0001711279-26-000071): "We expect the last patient visit for IOLITE in February 2027 with top-line results reported shortly thereafter." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000071/krys-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-26-000072): "The Company now expects the last patient visit in February 2027 with top-line results reported shortly thereafter." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000072/exhibit991-3q26pressrelease.htm
- ClinicalTrials.gov: "NCT07016750 (A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Krystal Biotech, Inc.." https://clinicaltrials.gov/study/NCT07016750

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kb803.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KB803 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kb803

```bibtex
@misc{secapidev_pdufa_kb803_20261116,
  title        = {KB803 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kb803}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kb803_20261116","title":"KB803 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kb803","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
